Shopping Cart

Close

No products in the cart.

๐’๐ฉ๐จ๐ญ๐ฅ๐ข๐ ๐ก๐ญ ๐จ๐ง ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก ๐ข๐ง ๐Œ๐€๐’๐‡

๐–๐จ๐ซ๐ฅ๐ ๐†๐ฅ๐จ๐›๐š๐ฅ ๐…๐š๐ญ๐ญ๐ฒ ๐‹๐ข๐ฏ๐ž๐ซ ๐ƒ๐š๐ฒ – ๐’๐ฉ๐จ๐ญ๐ฅ๐ข๐ ๐ก๐ญ ๐จ๐ง ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก ๐ข๐ง ๐Œ๐€๐’๐‡

Today is ๐–๐จ๐ซ๐ฅ๐ ๐๐€๐’๐‡ ๐ƒ๐š๐ฒ. Itโ€™s a time ๐ญ๐จ ๐ซ๐ž๐œ๐จ๐ ๐ง๐ข๐ณ๐ž ๐ญ๐ก๐ž ๐ซ๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก๐ž๐ซ๐ฌ, ๐œ๐ฅ๐ข๐ง๐ข๐œ๐ข๐š๐ง๐ฌ, ๐ข๐ง๐ฌ๐ญ๐ข๐ญ๐ฎ๐ญ๐ข๐จ๐ง๐ฌ ๐š๐ง๐ ๐œ๐จ๐ฆ๐ฉ๐š๐ง๐ข๐ž๐ฌ working to better understand NASHย and improve outcomes for patients.

 

In an era of data overload, ๐ฆ๐š๐ค๐ข๐ง๐  ๐ฌ๐ž๐ง๐ฌ๐ž ๐จ๐Ÿ ๐ฆ๐ฎ๐ฅ๐ญ๐ข๐ฉ๐ฅ๐ž ๐๐š๐ญ๐š๐ฌ๐ž๐ญ๐ฌ and ๐ฉ๐ซ๐จ๐ฆ๐จ๐ญ๐ข๐ง๐  ๐ญ๐ก๐ž ๐ฏ๐ข๐ฌ๐ข๐›๐ข๐ฅ๐ข๐ญ๐ฒ ๐จ๐Ÿ ๐ฆ๐ž๐๐ข๐œ๐š๐ฅ ๐ž๐ฑ๐ฉ๐ž๐ซ๐ญ๐ฌ is key.

 

To mark the day, weโ€™re sharing ๐š ๐ฌ๐ฅ๐ข๐๐ž๐ฌ๐ก๐จ๐ฐ ๐ก๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ข๐ง๐  ๐ค๐ž๐ฒ ๐๐š๐ญ๐š ๐ข๐ง ๐Œ๐€๐’๐‡ย ๐ซ๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก:
โ€ข A ๐˜จ๐˜ญ๐˜ฐ๐˜ฃ๐˜ข๐˜ญ ๐˜ฎ๐˜ข๐˜ฑ ๐˜ฐ๐˜ง ๐˜ต๐˜ฐ๐˜ฑ ๐˜ณ๐˜ฆ๐˜ด๐˜ฆ๐˜ข๐˜ณ๐˜ค๐˜ฉ๐˜ฆ๐˜ณ๐˜ด in MASH
โ€ข ๐˜ˆ๐˜ฏ๐˜ฏ๐˜ถ๐˜ข๐˜ญ ๐˜ต๐˜ณ๐˜ฆ๐˜ฏ๐˜ฅ๐˜ด in published research and clinical studies
โ€ข ๐˜”๐˜ข๐˜ช๐˜ฏ ๐˜ต๐˜ฐ๐˜ฑ๐˜ช๐˜ค๐˜ด in 2024/2025 publications
โ€ข ๐˜›๐˜ฐ๐˜ฑ 20 ๐˜ฆ๐˜น๐˜ฑ๐˜ฆ๐˜ณ๐˜ต๐˜ด based on impact and segmented on MASH
โ€ข ๐˜”๐˜ฐ๐˜ด๐˜ต ๐˜ข๐˜ค๐˜ต๐˜ช๐˜ท๐˜ฆ ๐˜ค๐˜ญ๐˜ช๐˜ฏ๐˜ช๐˜ค๐˜ข๐˜ญ ๐˜ด๐˜ช๐˜ต๐˜ฆ๐˜ด in Europe and US

 

This is a snapshot of where NASH research stands today โ€” and where it’s headed.

 

If you’re a ๐ฉ๐ก๐ฒ๐ฌ๐ข๐œ๐ข๐š๐ง ๐จ๐ซ ๐ฌ๐œ๐ข๐ž๐ง๐ญ๐ข๐ฌ๐ญ ๐ฐ๐จ๐ซ๐ค๐ข๐ง๐  ๐ข๐ง NASH ๐จ๐ซ ๐ซ๐ž๐ฅ๐š๐ญ๐ž๐ ๐š๐ซ๐ž๐š๐ฌ, join ScienceLeadR. Register or Log in with your ORCID, claim your profile,
and connect with peers focused on NASH research:https://lnkd.in/gJew3DBz

 

๐…๐ข๐ง๐ ๐œ๐จ๐ฅ๐ฅ๐š๐›๐จ๐ซ๐š๐ญ๐จ๐ซ๐ฌ, ๐ฌ๐ก๐š๐ซ๐ž ๐ฒ๐จ๐ฎ๐ซ ๐ฐ๐จ๐ซ๐ค, ๐š๐ง๐ ๐ฌ๐ญ๐š๐ฒ ๐ฎ๐ฉ๐๐š๐ญ๐ž๐ with whatโ€™s happening in the field.

 

Together, we can ๐๐ซ๐ข๐ฏ๐ž ๐ข๐ง๐ง๐จ๐ฏ๐š๐ญ๐ข๐จ๐ง ๐š๐ง๐ ๐ข๐ฆ๐ฉ๐ซ๐จ๐ฏ๐ž ๐จ๐ฎ๐ญ๐œ๐จ๐ฆ๐ž๐ฌ for patients with or at-risk of MASH.
NASH Insights

WorldNASHDay NASH MASH MedicalResearch ScientificExperts ClinicalTrials #KOL LifeSciences AI PatientsFirst

Leave a Reply

Your email address will not be published. Required fields are marked *